AMAlanna M. Manning

Alanna M. Manning

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alanna M. Manning has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Clearance of Human Cytomegalovirus Using CRISPR/Cas9 RNA Lipid Nanoparticles

    by Yan Ming Anson Lau, Janice Pang, Meng Qi Jiang, Yikai Sun, Karlene L. M. Knaggs, Grayson Tilstra, Ana-Maria Oproescu, Julien Couture-Senecal, Alanna M. Manning, Ranim Maaieh, et al.

    Human cytomegalovirus (HCMV), a DNA virus, poses significant health risks to immunocompromised and immunosuppressed individuals and newborns. Clinical antiviral drugs like ganciclovir inhibit viral replication but have toxicities, are ineffective against drug-resistant strains, and cannot destroy HCMV DNA. CRISPR/Cas9 can cleave DNA, but has not been used therapeutically to target and degrade HCMV DNA in cells post-infection. We developed an all-in-one CRISPR/Cas9 RNA lipid nanoparticle (LNP) that clears established HCMV infections, permits rapid updating to combat resistance and is effective against multiple strains. Bioinformatic analyses identified essential, conserved viral genes as CRISPR/Cas9 targets. A delivery material screen revealed that antiviral activity was dependent on the ionizable lipid and LNP composition. Our lead formulation, βN2-40, inhibited up to 93.5% of HCMV infection with a single treatment. Furthermore, multitargeting βN2-40 LNPs demonstrated antiviral kinetics and a safety profile similar to ganciclovir, making it a compelling alternative to existing small-molecule antiviral drugs.

  • Top Cited Papers

    Iterative Design of Ionizable Lipids for Intramuscular mRNA Delivery

    by Grayson Tilstra, Julien Couture-Senécal, Yan Ming Anson Lau, Alanna M. Manning, Daniel S. M. Wong, Wanda W. Janaeska, Titobioluwa A. Wuraola, Janice Pang, Omar F. Khan

    Lipid nanoparticles (LNPs) are the most clinically advanced delivery vehicles for RNA and have enabled the development of RNA-based drugs such as the mRNA COVID-19 vaccines. Functional delivery of mRNA by an LNP greatly depends on the inclusion of an ionizable lipid, and small changes to these lipid structures can significantly improve delivery. However, the structure-function relationships between ionizable lipids and mRNA delivery are poorly understood, especially for LNPs administered intramuscularly. Here, we show that the iterative design of a novel series of ionizable lipids generates key structure-activity relationships and enables the optimization of chemically distinct lipids with efficacy that is on-par with the current state of the art. We find that the combination of ionizable lipids comprising an ethanolamine core and LNPs with an apparent pKa between 6.6 and 6.9 maximizes intramuscular mRNA delivery. Furthermore, we report a nonlinear relationship between the lipid-to-mRNA mass ratio and protein expression, suggesting that a critical mass ratio exists for LNPs and may depend on ionizable lipid structure. Our findings add to the mechanistic understanding of ionizable lipids and demonstrate that hydrogen bonding, ionization behavior, and lipid-to-mRNA mass ratio are key design parameters affecting intramuscular mRNA delivery. We validate these insights by applying them to the rational design of new ionizable lipids. Overall, our iterative design strategy efficiently generates potent ionizable lipids. This hypothesis-driven method reveals structure-activity relationships that lay the foundation for the optimization of ionizable lipids in future LNP-RNA drugs. We foresee that this design strategy can be extended to other optimization parameters beyond intramuscular expression.